Literature DB >> 25648997

A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Dan Tian1, Natalia M Solodin1, Prashant Rajbhandari1, Kelsi Bjorklund1, Elaine T Alarid1, Pamela K Kreeger2.   

Abstract

Receptor levels are a key mechanism by which cells regulate their response to stimuli. The levels of estrogen receptor-α (ERα) impact breast cancer cell proliferation and are used to predict prognosis and sensitivity to endocrine therapy. Despite the clinical application of this information, it remains unclear how different cellular processes interact as a system to control ERα levels. To address this question, experimental results from the ERα-positive human breast cancer cell line (MCF-7) treated with 17-β-estradiol or vehicle control were used to develop a mass-action kinetic model of ERα regulation. Model analysis determined that RNA dynamics could be captured through phosphorylated ERα (pERα)-dependent feedback on transcription. Experimental analysis confirmed that pERα-S118 binds to the estrogen receptor-1 (ESR1) promoter, suggesting that pERα can feedback on ESR1 transcription. Protein dynamics required a separate mechanism in which the degradation rate for pERα was 8.3-fold higher than nonphosphorylated ERα. Using a model with both mechanisms, the root mean square error was 0.078. Sensitivity analysis of this combined model determined that while multiple mechanisms regulate ERα levels, pERα-dependent feedback elicited the strongest effect. Combined, our computational and experimental results identify phosphorylation of ERα as a critical decision point that coordinates the cellular circuitry to regulate ERα levels. © FASEB.

Entities:  

Keywords:  feedback; mathematical modeling; nuclear receptor; systems biology

Mesh:

Substances:

Year:  2015        PMID: 25648997      PMCID: PMC4415015          DOI: 10.1096/fj.14-265637

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  63 in total

Review 1.  Coregulators of estrogen receptor action.

Authors:  Gilles B Tremblay; Vincent Giguère
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2002       Impact factor: 1.807

Review 2.  Mechanisms of tamoxifen resistance.

Authors:  Alistair Ring; Mitch Dowsett
Journal:  Endocr Relat Cancer       Date:  2004-12       Impact factor: 5.678

3.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.

Authors:  E T Alarid; N Bakopoulos; N Solodin
Journal:  Mol Endocrinol       Date:  1999-09

5.  CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome.

Authors:  Mathilde Calligé; Isabelle Kieffer; Hélène Richard-Foy
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

Review 6.  Steroid hormone receptors in breast cancer management.

Authors:  C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

7.  Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites.

Authors:  Christian Atsriku; David J Britton; Jason M Held; Birgit Schilling; Gary K Scott; Bradford W Gibson; Christopher C Benz; Michael A Baldwin
Journal:  Mol Cell Proteomics       Date:  2008-11-03       Impact factor: 5.911

8.  Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen.

Authors:  Christopher C Valley; Natalia M Solodin; Ginny L Powers; Stephanie J Ellison; Elaine T Alarid
Journal:  J Mol Endocrinol       Date:  2008-01       Impact factor: 5.098

9.  Biological heterogeneity of ER-positive breast cancers in the post-menopausal population.

Authors:  S Romain; O Chinot; O Guirou; M Soullière; P M Martin
Journal:  Int J Cancer       Date:  1994-10-01       Impact factor: 7.396

Review 10.  Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

Authors:  Rocío García-Becerra; Nancy Santos; Lorenza Díaz; Javier Camacho
Journal:  Int J Mol Sci       Date:  2012-12-20       Impact factor: 5.923

View more
  5 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

2.  The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.

Authors:  Berry Button; Sarah Croessmann; David Chu; D Marc Rosen; Daniel J Zabransky; W Brian Dalton; Karen Cravero; Kelly Kyker-Snowman; Ian Waters; Swathi Karthikeyan; Eric S Christenson; Josh Donaldson; Tasha Hunter; Lauren Dennison; Cody Ramin; Betty May; Richard Roden; Dana Petry; Deborah K Armstrong; Kala Visvanathan; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2018-12-17       Impact factor: 4.872

Review 3.  Physiological significance of bistable circuit design in metabolic homeostasis: role of integrated insulin-glucagon signalling network.

Authors:  Manu Tomar; Pramod R Somvanshi; Venkatesh Kareenhalli
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.742

4.  DNA methylation and expression of estrogen receptor alpha in fathead minnows exposed to 17α-ethynylestradiol.

Authors:  J K Fetke; J W Martinson; R W Flick; W Huang; D C Bencic; M J See; E M Pilgrim; R W Debry; A D Biales
Journal:  Aquat Toxicol       Date:  2021-02-23       Impact factor: 4.964

5.  RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha.

Authors:  Katarzyna A Ludwik; Zachary M Sandusky; Kimberly M Stauffer; Yu Li; Kelli L Boyd; George A O'Doherty; Thomas P Stricker; Deborah A Lannigan
Journal:  Cell Rep       Date:  2020-07-21       Impact factor: 9.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.